TRUMY:OTO-Terumo Corp. ADR (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 16.41

Change

-0.03 (-0.18)%

Market Cap

USD 12.77B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-17 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+4.57 (+2.00%)

USD 105.29B
ESLOY Essilor International SA

+2.32 (+2.02%)

USD 104.03B
HOCPY Hoya Corp

+5.70 (+4.16%)

USD 48.28B
HOCPF HOYA Corporation

N/A

USD 48.05B
CLPBY Coloplast A

-0.12 (-0.91%)

USD 31.20B
CLPBF Coloplast A/S

N/A

USD 30.31B
TRUMF Terumo Corporation

+0.14 (+0.79%)

USD 27.88B
SAUHF Straumann Holding AG

+5.10 (+3.42%)

USD 24.11B
OCPNF Olympus Corporation

N/A

USD 21.30B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.04B

ETFs Containing TRUMY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 101.23% 98% N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.23% 95% A 93% A
Trailing 12 Months  
Capital Gain 101.41% 93% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.41% 90% A- 92% A
Trailing 5 Years  
Capital Gain 126.66% 100% F 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 126.66% 98% N/A 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 7.22% 49% F 52% F
Dividend Return 7.22% 45% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 35.76% 67% D+ 63% D
Risk Adjusted Return 20.18% 59% D- 55% F
Market Capitalization 12.77B 89% A- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.